In June, Sinovation, the leading domestic neurosurgery intelligent platform for diagnosis and minimally invasive surgery, announced the completion of a super-billion D+ round financing. The investors in this round include Xinda Kunpeng, TsingVentures, Peakvest, and Huiyu Investment, with existing shareholder DNV Capital increasing its investment. With this, Sinovation's D+ round financing is now concluded.

CEC Capital continued to serve as the exclusive financial advisor for Sinovation in this transaction.

Following the acquisition of Beijing Huake Hengsheng Medical Technology Co., Ltd. by Sinovation in 2022, the company's independently developed flagship product, the "Magnetic Resonance Monitoring Laser Ablation System (LITT)," was approved for listing in April 2023. This system became the world's first magnetic resonance monitoring laser ablation treatment system for the brain developed by a Chinese company and the only one approved for domestic use. Additionally, the company will further accelerate the expansion of this product in other intracranial indications, providing revolutionary and innovative treatment options for a wide range of domestic epilepsy and intracranial tumor patients, offering them safe, precise, and minimally invasive treatments.